Kymera Therapeutics KYMR
NASDAQ KYMR
$129.46 -5.38 (-3.99%)
As of: Nov 12, 2026 · 11:02 AM EST

Kymera Therapeutics (KYMR) Return on Sales [ROS] (2019 - 2026)

Updated

Kymera Therapeutics' Return on Sales [ROS] came in at -116.32% for Q2 2026, up 620.50 percentage points from -736.82% a year earlier and up 128.56 percentage points from the prior quarter.

Analysis

Kymera Therapeutics (KYMR) Return on Sales [ROS] (2019 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Kymera Therapeutics reported Return on Sales [ROS] of -333.51%, up 364.00 percentage points year-over-year; for FY2025, it came in at -891.07%, down 335.26 percentage points from FY2024.

  • Return on Sales [ROS] carries a five-year change of -755.02 percentage points (FY2020 to FY2025).
  • Going back by year, Return on Sales [ROS] was -555.82% in FY2024 (-345.20 pp), -210.62% in FY2023 (+133.75 pp), -344.37% in FY2022 (-206.34 pp) and -138.03% in FY2021 (-1.98 pp).
  • The Q2 2026 figure represents the highest quarterly Return on Sales [ROS] since Q4 2023.
  • Year-over-year, Return on Sales [ROS] increased in three of the last eight quarters, with an average year-over-year change of -637.77 percentage points.
  • The fastest year-over-year change in Return on Sales [ROS] over five years came in Q2 2026 (a gain of 620.50 percentage points), and the weakest in Q4 2025 (a drop of 2318.84 percentage points).
  • Business Quant data shows KYMR's Return on Sales [ROS] at -244.88% (Q1 2026), -3411.01% (Q4 2025) and -3347.36% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Kymera Therapeutics 11.66 Bn 8.50 Bn - -396.04%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -396.04%
Jun 30, 2026 -116.32%
Mar 31, 2026 -244.88%
Dec 31, 2025 -3,411.01%
Sep 30, 2025 -3,347.36%
Jun 30, 2025 -736.82%
Mar 31, 2025 -336.77%
Dec 31, 2024 -1,092.17%
Sep 30, 2024 -1,927.93%
Jun 30, 2024 -198.54%
Mar 31, 2024 -562.18%
Dec 31, 2023 -40.33%
Sep 30, 2023 -1,216.35%
Jun 30, 2023 -262.72%
Mar 31, 2023 -478.83%
Dec 31, 2022 -239.36%
Sep 30, 2022 -469.92%
Jun 30, 2022 -354.44%
Mar 31, 2022 -383.84%
Dec 31, 2021 -222.55%
API Access

Kymera Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=KYMR&period=max&api_key=YOUR_API_KEY